News Update FDA Extends Market Exclusivi

News Update FDA Extends Market Exclusivity Six Months for BioMarin’s Rare Disease Therapy KUVAN(R) (Sapropterin Dihydrochloride) Powder for Oral Solution and Tablets http://ow.ly/2FHKfa

Advertisements